Biodexa Pharmaceticals (BDRX : NASDAQ)
Common Stock
$0.48
USD
+0.13 (38.46%)
Last updated: 2026-10-14
Follow BDRX
BDRX
Biodexa Pharmaceticals
WealthAwesomePerformance
1 Day
+38.46%
1 Week
-13.99%
1 Month
-56.71%
YTD
-83.89%
Key Statistics
Market Cap
$1.07M
52W High
$44.70
52W Low
$0.34
P/E Ratio
0.01
50 Day MA
$0.97
200 Day MA
$3.91
Beta
1.28
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/14/2026 | $0.50 | $0.54 | $0.40 | $0.48 | $0.48 | 53,043,207 |
| 10/13/2026 | $0.42 | $0.42 | $0.34 | $0.35 | $0.35 | 13,837,019 |
| 10/12/2026 | $0.47 | $0.47 | $0.38 | $0.38 | $0.38 | 265,089 |
| 10/9/2026 | $0.52 | $0.52 | $0.45 | $0.46 | $0.46 | 156,800 |
| 10/8/2026 | $0.55 | $0.55 | $0.51 | $0.52 | $0.52 | 105,900 |
| 10/7/2026 | $0.57 | $0.59 | $0.53 | $0.56 | $0.56 | 148,340 |
| 10/6/2026 | $0.62 | $0.64 | $0.59 | $0.60 | $0.60 | 254,987 |
| 10/5/2026 | $0.62 | $0.62 | $0.60 | $0.61 | $0.61 | 103,122 |
| 10/2/2026 | $0.63 | $0.63 | $0.57 | $0.62 | $0.62 | 185,800 |
| 10/1/2026 | $0.67 | $0.67 | $0.60 | $0.63 | $0.63 | 251,789 |
Analyst Price Targets
Based on analyst covering BDRX · as of Oct 15, 2026
Wall Street analysts forecast BDRX stock price to rise 1739.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$8.92
+1739.7% Upside
Previously US$8.93 on Oct 14, 2026
Current Price
US$0.48
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BDRX's historical volatility
30-Day Vol
277.1%
Annualized
90-Day Vol
183.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.46 | US$0.18 – US$1.19 |
| 60 trading days | US$0.43 | US$0.11 – US$1.66 |
| 90 trading days | US$0.41 | US$0.08 – US$2.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Financials
- Revenue (TTM)
- $83,000
- EBITDA
- $-8.85M
- Profit Margin
- 0.00%
- ROE (TTM)
- -42.00%
- EPS (Diluted)
- 87.01
- Book Value
- 17.08
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About BDRX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NVNI | Nvni Group Limited Ordinary Shares | $0.53 | +382.56% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +150.56% |
| SOBR | Sobr Safe Inc | $0.08 | +94.88% |
| GLND | Greenland Energy Company Common Stock | $3.90 | +76.47% |
| TGL | Treasure Global Inc. | $0.45 | +61.87% |
| NIVF | NewGenIvf Group Limited Class A Ordinary Shares | $0.29 | +50.20% |
| CRANR | Crane Harbor Acquisition Corp. II Rights | $0.16 | +45.47% |
| HCICR | Hennessy Capital Investment Corp. VIII Share Rights | $0.12 | +41.53% |